# Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

> **NCT03256045** · PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 9 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **OTHER:** Chemosensitivity Assay
- **DRUG:** Dexamethasone
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Panobinostat

## Key facts

- **NCT ID:** NCT03256045
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-08
- **Primary completion:** 2021-02-05
- **Final completion:** 2021-02-05
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Terminated due to loss of funding and former PI left the institution
- **Last updated:** 2022-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03256045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03256045, "Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03256045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*